Gefitinib

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Conditions

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Trial Timeline

Sep 1, 2010 → Jun 1, 2016

NCT ID

NCT01203917

About Gefitinib

Gefitinib is a approved stage product being developed by AstraZeneca for Caucasian Patients With EGFR Mutation Positive Advanced NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT01203917. Target conditions include Caucasian Patients With EGFR Mutation Positive Advanced NSCLC.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00268255	Phase 1/2	Withdrawn	—	—	Non-small Cell Lung Cancer
NCT01510990	Phase 2	UNKNOWN	Apr 1, 2012	Nov 1, 2015	Non-small Cell Lung Cancer
NCT01405846	Phase 2	Terminated	Dec 1, 2011	Jun 1, 2016	Lung Cancer
NCT01203917	Approved	Completed	Sep 1, 2010	Jun 1, 2016	Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
NCT00608868	Approved	Completed	Jan 1, 2007	Jan 1, 2009	Non Small Cell Lung Carcinoma
NCT00372515	Phase 1	Completed	Jun 1, 2006	Apr 1, 2015	Non-Small Cell Lung Cancer
NCT00344773	Phase 2	Completed	Mar 1, 2006	Dec 1, 2007	Pulmonary Cancer
NCT00455936	Phase 3	Completed	Oct 1, 2005	Mar 1, 2010	Lung Cancer
NCT00127829	Phase 1	Completed	Jul 1, 2005	Jan 1, 2008	Tumors
NCT00198380	Phase 2	Completed	Apr 1, 2005	Dec 1, 2009	Pneumonic-type Adenocarcinoma (P-ADC)
NCT00519077	Phase 2	Completed	Mar 1, 2005	May 1, 2013	Head and Neck Neoplasms
NCT00188617	Phase 2	Completed	Jan 1, 2005	Nov 1, 2009	LUNG CANCER
NCT00357734	Phase 3	Completed	Jan 1, 2005	May 1, 2015	Lung Cancer
NCT00239343	Phase 2	Completed	Oct 1, 2004	May 1, 2007	Breast Cancer
NCT00298688	Phase 2	Completed	Sep 1, 2004	Mar 1, 2007	Small Cell Lung Cancer
NCT00177242	Phase 2	Completed	Sep 1, 2004	Dec 1, 2006	Cancer
NCT00259064	Phase 2/3	Completed	Sep 1, 2004	Apr 1, 2016	NSCLC
NCT00228488	Phase 2	Completed	Jun 1, 2004	Dec 1, 2005	Head and Neck Cancer
NCT00509002	Phase 2	Completed	May 1, 2004	Sep 1, 2016	Salivary Gland Cancer
NCT00255489	Phase 1	Completed	May 1, 2004	Jun 1, 2006	Non-small-cell Lung Cancer

Competing Products

2 competing products in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

See all competitors

Product	Company	Stage	Hype Score
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
UCB0942	UCB	Phase 1	29